Brief: Ultragenyx Announces FDA Clearance Of Investigational New Drug (Ind) Application For Ux016
30/03/2026 15:10
March 30 (Reuters) - Ultragenyx Pharmaceutical Inc RARE.O: ULTRAGENYX ANNOUNCES FDA CLEARANCE OF INVESTIGATIONAL NEW DRUG (IND) APPLICATION FOR UX016, A SIALIC ACID PRODRUG FOR THE TREATMENT OF GNE MYOPATHY ULTRAGENYX PHARMACEUTICAL INC - PHASE 1/2 STUDY OF UX016 EXPECTED TO BEGIN IN H2 2026 Source text: ID:nGNX30Mbv Further company coverage: RARE.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ultragenyx Pharmaceutical
See all newsBrief: Ultragenyx Pharmaceutical Enters Settlement Agreement With Navinta On Dojolvi Patent Litigation - SEC Filing
Ultragenyx gains on $210 million US FDA voucher sale
Brief: Ultragenyx Pharmaceutical - Under Deal With U.S. Department Of Health Co To Pay 20% Of Prv Sale Proceeds To Nih
Brief: Ultragenyx Enters Into Agreement To Sell Rare Pediatric Disease Priority Review Voucher For $210 Million
U.S. STOCKS ON THE MOVE-CoreWeave, StubHub, Ultragenyx